- Home
- IEX vs MRNA Comparison
IEX vs MRNA Comparison
Compare IEX & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IEX
- MRNA
- Stock Information
- Founded
- IEX 1987
- MRNA 2010
- Country
- IEX United States
- MRNA United States
- Employees
- IEX N/A
- MRNA N/A
- Industry
- IEX Fluid Controls
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IEX Industrials
- MRNA Health Care
- Exchange
- IEX Nasdaq
- MRNA Nasdaq
- Market Cap
- IEX 16.3B
- MRNA 16.0B
- IPO Year
- IEX 1991
- MRNA 2018
- Fundamental
- Price
- IEX $192.42
- MRNA $35.53
- Analyst Decision
- IEX Buy
- MRNA Hold
- Analyst Count
- IEX 8
- MRNA 20
- Target Price
- IEX $241.71
- MRNA $59.65
- AVG Volume (30 Days)
- IEX 569.1K
- MRNA 13.6M
- Earning Date
- IEX 02-04-2025
- MRNA 02-14-2025
- Dividend Yield
- IEX 1.45%
- MRNA N/A
- EPS Growth
- IEX N/A
- MRNA N/A
- EPS
- IEX 6.64
- MRNA N/A
- Revenue
- IEX $3,268,800,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- IEX $8.45
- MRNA N/A
- Revenue Next Year
- IEX $6.46
- MRNA $22.19
- P/E Ratio
- IEX $28.75
- MRNA N/A
- Revenue Growth
- IEX N/A
- MRNA N/A
- 52 Week Low
- IEX $189.51
- MRNA $29.25
- 52 Week High
- IEX $246.36
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- IEX 33.49
- MRNA 48.60
- Support Level
- IEX $194.44
- MRNA $32.78
- Resistance Level
- IEX $199.97
- MRNA $36.98
- Average True Range (ATR)
- IEX 4.34
- MRNA 2.50
- MACD
- IEX -0.75
- MRNA 0.30
- Stochastic Oscillator
- IEX 10.77
- MRNA 66.81
About IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. Based in Lake Forest, Illinois, Idex has manufacturing operations in over 20 countries and has over 7,000 employees. The company generated $3.3 billion in revenue in 2023.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.